• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:13:48 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email
    SC 13G/A 1 b021221a.htm SCHEDULE 13G (AMENDMENT #1)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    (Name of Issuer)
    Aptevo Therapeutics Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.001 Per Share

    (CUSIP Number)

    03835L108

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).




    CUSIP No. 03835L108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions)
    PN
     


    CUSIP No. 03835L108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 03835L108
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              7 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       7 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    7 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 03835L108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              7 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       7 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    7 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Aptevo Therapeutics Inc.
    Item 1(b) Address of issuer's principal executive offices:
    2401 4th Avenue, Suite 1050, Seattle, Washington 98121
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.001 per
    share (“Common Stock”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to shares of
    Common Stock held by certain investment funds managed by Point72 Asset Management; (iii)
    Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to shares of
    Common Stock held by certain investment funds it manages; and (iv) Steven A. Cohen (“Mr.
    Cohen”) with respect to shares of Common Stock beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY
    10001.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company. Mr.
    Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.001 Per Share
    2(e) CUSIP Number:
    03835L108

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2020:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 7
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 7 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 7

    4. Steven A. Cohen
    (a) Amount beneficially owned: 7
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 7
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 7
    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no shares of Common Stock. Pursuant to an
    investment management agreement, Point72 Asset Management maintains investment
    and voting power with respect to the securities held by certain investment funds it
    manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset
    Management. Pursuant to an investment management agreement, Cubist Systematic
    Strategies maintains investment and voting power with respect to the securities held by
    certain investment funds it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.  As of
    December 31, 2020, by reason of the provisions of Rule 13d-3 of the Exchange Act, as
    amended, each of Cubist Systematic Strategies and Mr. Cohen may be deemed to
    beneficially own 7 shares of Common Stock (constituting <0.1% of the shares of
    Common Stock outstanding). Each of Point72 Asset Management, Point72 Capital
    Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen disclaims beneficial
    ownership of any of the securities covered by this statement.
    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, and other than
    activities solely in connection with a nomination under § 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 16, 2021

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $APVO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

      Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

      1/15/25 8:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

      SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

      12/12/24 12:50:00 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

      Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

      12/12/24 9:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huebner Dirk claimed no ownership of stock in the company (SEC Form 3)

      3 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      7/9/25 5:32:20 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GC, BD & Corp Affairs Kwon Soyoung converted options into 4 shares, increasing direct ownership by 19% to 25 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:36:04 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Lamothe Jeffrey G. converted options into 5 shares, increasing direct ownership by 16% to 36 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:35:19 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Aptevo Therapeutics Inc.

      SCHEDULE 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      7/8/25 2:11:55 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aptevo Therapeutics Inc.

      DEF 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/7/25 12:11:40 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/1/25 5:05:48 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

      Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

      5/28/21 8:33:45 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

      SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/14/24 3:45:38 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/8/24 2:57:35 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      2/14/24 3:24:02 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care